title: Selective PPAR modulators (SPPARs) may fill the need for treatment of the atherogenic dyslipidemia of insulin resistance and type 2 diabetes: Can they reduce the associated cardiac risk?
authors.affiliation: Lakegatan 22, 42658, Gothenburg, Västra Frölunda, Sweden. Electronic address: german.camejo@telia.com.
authors.forename: Germán
authors.initials: G
authors.lastname: Camejo
mesh_terms: D050197:Atherosclerosis; D003924:Diabetes Mellitus, Type 2; D050171:Dyslipidemias; D006801:Humans; D007333:Insulin Resistance; D047493:PPAR alpha; D047495:PPAR gamma; D047492:Peroxisome Proliferator-Activated Receptors
chemical_list: D047493:PPAR alpha; D047495:PPAR gamma; D047492:Peroxisome Proliferator-Activated Receptors
keywords: Atherosclerosis; Dyslipidemia; Fibrates; Inflammation; Mouse models; PPAR agonists; Reverse cholesterol transport; Selective PPARα modulators (SPPARMα)